» Articles » PMID: 31322815

Combined and Differential Effects of Alpha-thalassemia and HbF-quantitative Trait Loci in Senegalese Hydroxyurea-free Children with Sickle Cell Anemia

Abstract

Background: Our objective was to investigate the combined and differential effects of alpha-thalassemia -3.7 kb deletion and HbF-promoting quantitative trait loci (HbF-QTL) in Senegalese hydroxyurea (HU)-free children and young adults with sickle cell anemia (SCA).

Procedure: Steady-state biological parameters and vaso-occlusive crises (VOC) requiring emergency admission were recorded over a 2-year period in 301 children with SCA. The age of the first hospitalized VOC was also recorded. These data were correlated with the alpha-globin and HbF-QTL genotypes. For the latter, three different genetic loci were studied (XmnI, rs7482144; BCL11A, rs1427407; and the HBS1L-MYB region, rs28384513) and a composite score was calculated, ranging from zero (none of these three polymorphisms) to six (all three polymorphisms at the homozygous state).

Results: A positive clinical impact of the HbF-QTL score on VOC rate, HbF, leucocytes, and C-reactive protein levels was observed only for patients without alpha-thalassemia deletion. Conversely, combination of homozygous -3.7 kb deletion with three to six HbF-QTL was associated with a higher VOC rate. The age of the first hospitalized VOC was delayed for patients with one or two alpha-thalassemia deletions and at least two HbF-QTL.

Conclusion: Alpha-thalassemia -3.7 kb deletion and HbF-QTL are modulating factors of SCA clinical severity that interact with each other. They should be studied and interpreted together and not separately, at least in HU-free children.

Citing Articles

Transcriptional regulators of fetal hemoglobin.

Dos Santos G, Rabi L, Bezerra A, da Cunha M, Iatecola A, Fernandes V Hematol Transfus Cell Ther. 2024; 46 Suppl 5:S258-S268.

PMID: 39237431 PMC: 11670590. DOI: 10.1016/j.htct.2024.06.001.


Association of gene polymorphism (rs724016) with height and fetal hemoglobin in individuals with sickle cell anemia.

Costa-Junior D, Souza Valente T, Rolim Belisario A, Carvalho G, Madeira M, Velloso-Rodrigues C Mol Genet Metab Rep. 2024; 39:101086.

PMID: 38800625 PMC: 11127270. DOI: 10.1016/j.ymgmr.2024.101086.


Genetic Variation and Sickle Cell Disease Severity: A Systematic Review and Meta-Analysis.

Kirkham J, Estepp J, Weiss M, Rashkin S JAMA Netw Open. 2023; 6(10):e2337484.

PMID: 37851445 PMC: 10585422. DOI: 10.1001/jamanetworkopen.2023.37484.


Fetal hemoglobin-boosting haplotypes of BCL11A gene and HBS1L-MYB intergenic region in the prediction of clinical and hematological outcomes in a cohort of children with sickle cell anemia.

Sales R, Nogueira B, Rolim Belisario A, Faria G, Mendes F, Viana M J Hum Genet. 2022; 67(12):701-709.

PMID: 36167770 DOI: 10.1038/s10038-022-01079-0.


Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea.

Allard P, Alhaj N, Lobitz S, Cario H, Jarisch A, Grosse R Haematologica. 2021; 107(7):1577-1588.

PMID: 34706496 PMC: 9244815. DOI: 10.3324/haematol.2021.278952.